DZ Bank lifted its fair value estimate on Bayer from EUR 60 to EUR 64 on Wednesday while keeping its “Buy” rating, adding a second day of analyst tailwind after the German group’s quarterly update. The shares rose 2.7% on the session, with the improved outlook published Tuesday and the strength of the pharmaceuticals business cited as the drivers. Media reports pointed to UBS and Goldman Sachs raising their price targets to EUR 66 apiece a day earlier.
The re-rating follows a guidance bump that gives the bulls something concrete to work with. Bayer now expects EBITDA before special items of EUR 9.8bn to EUR 10.3bn for full-year 2026, up from a prior range of EUR 9.6bn to EUR 10.1bn. Management tied the upgrade to the momentum in its drug division.
Third-quarter base sets the starting line
Reported group revenue for the third quarter of 2026 came in at EUR 10.053bn, a nominal increase of 4.1%. Stripping out currency effects and portfolio changes, the top line grew 1.9%. EBITDA before special items advanced 6.9% year on year to EUR 1.615bn.
Those figures describe what has already been delivered. The pipeline news sits on a different plane. Bayer announced on Wednesday that Sevabertinib won first-line approval in China for adults with unresectable, locally advanced or metastatic HER2-mutant non-small cell lung cancer. The decision rests on data from the ongoing Phase I/II SOHO-01 trial, making it a regulatory ruling in hand rather than a review still pending.
The distinction matters for anyone building a thesis on the stock. An approval creates the conditions for treating patients in the cleared indication; it does not by itself establish a revenue contribution. Sevabertinib joins Asundexian, which was cleared in China on 26 October for reducing stroke risk in adults after a non-cardioembolic ischaemic stroke or a high-risk TIA. Two green lights in separate therapeutic areas offer a broader base than a single asset would — though concrete earnings impact cannot be inferred from the approvals alone.
The legal overhang gets a data point
On the litigation front, all jurors in the first glyphosate trial since the US Supreme Court’s ruling sided with Monsanto on 29 October. According to Bayer, the plaintiffs could not prove their claims. That is a completed verdict, not a declaration that all glyphosate risk has been retired.
Should investors sell immediately? Or is it worth buying Bayer?
Separately, CEO Bill Anderson expects a decision on the proposed USD 7.25bn Roundup settlement before Christmas, Reuters reported Tuesday. A Missouri court is reviewing the proposed terms.
Where the story gets harder
The counterweight to the pharma narrative is the balance sheet. Bayer’s upgraded free cash flow guidance for 2026 still points to an outflow of EUR 1.5bn to EUR 0.5bn. Net financial debt at year-end is projected at EUR 28bn to EUR 29bn, an improvement on prior expectations but hardly a clean bill of health.
A stronger operating result and fresh approvals do not automatically solve that. The quality of the improvement is what counts: earnings gains would carry more weight if they showed up in the cash flow line. If they do not, the financial position could cap the valuation despite the medical progress.
What to watch next
Bayer plans to present new data on cardiovascular disease, kidney conditions and stroke at the American Heart Association’s 2026 scientific sessions. Those presentations serve a different purpose than quarterly numbers — they can sharpen the medical case without substituting for proof of commercial returns.
The bull case holds together as long as Bayer carries the raised earnings guidance and converts its pipeline wins into economic results. Should the earnings support weaken, or should cash flow lag the improved target, the thesis loses its force. A regulatory approval and a group-level target answer different questions, and investors will need both answered before the re-rating is fully earned.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from November 5 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 5.
Bayer: Buy or sell? Read more here...
